-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $11

Benzinga·02/25/2026 15:57:48
Listen to the news
Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $10 to $11.